ServicenavigationHauptnavigationTrailKarteikarten


Research unit
INNOSUISSE
Project number
11020.1;7 PFLS-LS
Project title
Simulation Framework for the Development of Accommodating Intraocular Lenses (ASF)

Texts for this project

 GermanFrenchItalianEnglish
Short description
-
-
-
Anzeigen
Abstract
-
-
-
Anzeigen

Inserted texts


CategoryText
Short description
(English)
Simulation Framework for the Development of Accommodating Intraocular Lenses (ASF)
Abstract
(English)
Accommodation is the process enabling the eye to change the point of focus from a distant object to a near object. Presbyopia is characterized as a progressive age related loss of accommodative amplitude. Its progression begins early in life, culminates in a complete loss of accommodation by about 50 years of age and affects 100% of the population. Presbyopia generally results in a need for a near spectacle correction or near addition lenses. On the other hand, cataract is the partial or complete loss of transparency in the crystalline lens, mainly as a result of aging. Cataracts are treated by removing the crystalline lens and replacing it with an artificial intraocular lens (IOL) what represents one of the most frequently performed surgery worldwide. Adoptics is developing an accommodating intraocular lens (AIOL) to treat cataract and restore accommodation. In this project the partners develop a framework for accommodation simulation (ASF) to test, optimize and accelerate time to market for Adoptics novel implant. Firstly, a toolset for numerical simulation of the accommodation process using the finite element method will provide better insight into the physiological aspects of presbyopia, which are currently not fully understood. Furthermore the finite element simulation models will allow for design optimization and pre-clinical verification of Adoptics AIOL. Secondly, optomechanical accommodation simulators will be developed and built to provide means for in-vitro validation and verification of numerical models and physical prototypes as well as for 100% quality control of the final AIOL implant.